חובות לטווח קצר של החברה: Regulus Therapeutics Inc. (RGLS)

The Regulus Therapeutics (RGLS) price chart demonstrates the dynamics of a company whose RNA therapy developments remain independent of economic cycles or inflation. The current indicator stands at 0.00, while the business faces a liquidity shortage due to research and development costs. However, ownership of exclusive patents for kidney treatment guarantees long-term collaboration with major market players and regular payments.

This indicator consolidates all obligations with a maturity of up to one year, allowing for an assessment of liquidity risk and working capital management efficiency through the company's solvency. For Regulus Therapeutics (RGLS), controlling these borrowings is critical when financing the expansion of miRNA drugs and scaling RGLS8429 clinical trials, as clearly reflected in the history of short-term credits and loans.